These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34281514)

  • 1. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
    Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
    BMC Cancer; 2021 Jul; 21(1):832. PubMed ID: 34281514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
    Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
    BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
    Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
    Sakai C; Shimokawa M; Iihara H; Fujita Y; Ikemura S; Hirose C; Kotake M; Funaguchi N; Gomyo T; Imai H; Hakamata J; Kaito D; Minato K; Arai T; Kawazoe H; Suzuki A; Ohno Y; Okura H
    Oncologist; 2021 Jun; 26(6):e1066-e1072. PubMed ID: 33811782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
    Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
    BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.
    Maeda A; Yoshida H; Inoue H; Ejiri M; Yamaguchi S; Kushihara H; Yamamoto Y; Ando Y; Sato Y; Tashiro Y; Hasegawa A; Takahara Y; Mizutani M; Oze I; Shimizu J
    Ann Palliat Med; 2021 Mar; 10(3):2699-2708. PubMed ID: 33615803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
    Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
    N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial.
    An Y; Zhang Z; Gu M; Zhao J; Jiang C; Zhao L; Jiang Y; Li H; Liu G; Jin G; Li Q
    Curr Pharm Des; 2023; 29(23):1867-1874. PubMed ID: 37539930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
    Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
    Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
    Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
    Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.
    Flank J; Schechter T; Gibson P; Johnston DL; Orsey AD; Portwine C; Sung L; Dupuis LL
    Support Care Cancer; 2018 Feb; 26(2):549-555. PubMed ID: 28856448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.
    Celio L; Saibene G; Lepori S; Festinese F; Niger M; Raspagliesi F; Lorusso D
    Tumori; 2019 Jun; 105(3):253-258. PubMed ID: 30945623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
    Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
    J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
    Furukawa N; Akasaka J; Shigemitsu A; Sasaki Y; Nagai A; Kawaguchi R; Kobayashi H
    Arch Gynecol Obstet; 2014 Apr; 289(4):859-64. PubMed ID: 24185939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.